39 results about "Prostate tumors" patented technology

The invention discloses an RGD modified crocetin-paclitaxel co-drug-loaded compound liposome and a preparation method and application thereof, and belongs to the technical field of biological medicines.The RGD modified crocetin-paclitaxel co-drug-loaded compound liposome comprises the following components: an RGD modified liposome, paclitaxel and crocetin, wherein the RGD modified lipidosome is used as a drug carrier, paclitaxel and crocetin are delivered to prostate tumor cells in a targeted manner, and the RGD modified lipidosome is prepared through a film dispersion method or a reverse evaporation method. The prostate cancer targeted compound liposome prepared by the invention can increase the uptake of prostate cancer cells, improve the in-vitro cytotoxicity of the prostate cancer cells to the prostate cancer cell line RM-1, inhibit the growth of RM-1 ectopic solid tumors in mice, and do not cause obvious damage to other tissues.

The invention relates to the use of a marker set comprising at least three substances selected from the group consisting of 5-hydroxymethyl-2-furancarboxylic acid, phenylacetylglutamine, N-acetylglutamine, L-tyrosine, dimethylamine, L-leucine, mannitol, sucrose, trigonelline, alanine and scyllo-inositol, in an in vitro method for determining the aggressiveness of a prostate tumor.

The invention discloses a prostate tumor steam ablation system and a using method thereof.The prostate tumor steam ablation system comprises operation equipment and a control host, and the operation equipment comprises an outer sleeve, a handle, a steam generator, a steam delivery needle, an angle sensor for obtaining the rotation angle of the steam delivery needle and delivery needle driving equipment; the end, away from the steam delivery needle, of the steam generator is connected with a sterile water inlet pipe. The end, away from the handle, of the outer sleeve is provided with a camera and integrated with a magnetic positioning sensor. The control host comprises a data processing control unit; the data processing control unit is used for processing prostate examination data of a patient before an operation to obtain a three-dimensional model of the prostate, determining a prostate tumor processing scheme according to user setting, and processing related data collected by the camera, the magnetic positioning sensor and the angle sensor to obtain a three-dimensional model of the outer sleeve and the steam delivery needle in the prostate. The steam ablation equipment is applied to the field of prostate tumor treatment for the first time, the treatment recovery time is short, and the male sexual function is reserved.

This invention relates to the field of biopharmaceutical technology, and in particular to the application of myrotoxin A in the preparation of drugs for treating prostate cancer. This invention is the first to discover the function of myrotoxin A in inducing ferroptosis in DU145 prostate cancer cells by targeting and inhibiting ACSL3 protein, and its inhibitory effect on prostate cancer proliferation. Specific embodiments of this invention reveal for the first time that myrotoxin A can precisely utilize the unique metabolic vulnerability of prostate cancer cells, significantly downregulating the expression of ACSL3 protein in DU145 cells at the protein level. This, in turn, by relieving the inhibition of ferroptosis by ACSL3 protein, specifically induces ferroptosis in prostate cancer cells, ultimately effectively inhibiting tumor cell growth and achieving the therapeutic goal of targeting prostate cancer development.

The invention discloses treatment equipment for reducing positive incisal margin after radical prostate resection, which comprises an injection device for injecting a PSMA probe into a body, a PET / CT (positron emission tomography / computed tomography) imaging device, a near-infrared fluorescence imaging device and a surgical robot, and is characterized in that the near-infrared fluorescence imaging device displays fluorescence levels of tumor tissues and normal tissues of the prostate of a patient injected with the probe; and carrying out fluorescence imaging on the prostate tumor tissue according to the fluorescence intensity of the probe in the urine. The treatment equipment disclosed by the invention is used for carrying out fluorescence imaging and accurate positioning on tumor tissues in an excision operation, the surgical robot is used for accurately excising the tumor tissues under fluorescence navigation, and the postoperative excision edge positive rate is obviously reduced; after the treatment equipment is adopted to carry out radical prostate resection, the biochemical recurrence risk of a patient is obviously reduced, and the prognosis is good; in addition, complications such as erectile dysfunction, urinary incontinence and urethrostenosis caused by injury of nerve and blood vessel bundles in an operation can be avoided, and the influence on the postoperative life quality of a patient is remarkably reduced.

The present invention discloses an application of a bromodomain protein 4 active compound based on a water network strategy. The bromodomain protein 4 active compound can be used to prepare a drug that inhibits the activity of bromodomain protein 4, and can be used to prepare a pharmaceutically acceptable salt. In addition, the bromodomain protein 4 active compound and the pharmaceutically acceptable salt prepared therefrom can also be used to prepare a bromodomain protein 4 inhibitor and the pharmaceutically acceptable salt prepared therefrom, as well as a pharmaceutical composition for preparing a prostate cancer cell proliferation inhibitor, an anti-prostate tumor drug, and a pharmaceutical composition for treating bromodomain protein 4-related diseases. The bromodomain protein 4 inhibitor prepared based on the bromodomain protein 4 active compound having obvious inhibitory activity of the present invention is applied to the treatment of diseases related to bromodomain protein 4, has high reliability, is easy to promote and popularize, and utilizes the potential advantages of the bromodomain protein 4 active compound as a drug or pharmaceutical composition, opening up a new approach for the treatment of related diseases.

The invention discloses a dynamic contrast enhanced magnetic resonance image analysis method suitable for prostate. The method comprises the following steps: extracting a concentration time signal of a contrast agent in a blood vessel from an iliac artery area of a dynamic contrast enhanced magnetic resonance image; performing nonlinear least square fitting on the DCE-MRI time signal intensity curve of each pixel point on the prostate by using a double-chamber exchange model to obtain a distribution diagram of three groups of physiological parameters of Ktrans, po and kio; and carrying out error analysis on kio to obtain a final distribution diagram of kio parameters and a distribution diagram of Ktrans and po parameters. According to the analysis method, the accuracy of physiological parameter estimation can be improved, and quantitative visual characterization of physiological characteristics of prostate tumors and normal tissues is achieved.

The invention relates to the technical field of urinary system disease diagnosis, in particular to a prostate tumor onset risk prediction method and system. By combining multiple groups of indexes and image group feature data, the prostate diseases, especially the prostate tumors, can be effectively evaluated, score data reflecting the state of the prostate tumors can be obtained, and the incidence probability and the staging result degree of the endometrial diseases can be more intuitively determined through the score data. Therefore, the overall automatic prediction of the prostate disease is realized.

The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

An exemplary embodiment of the present disclosure provides a compound of Formula (I):where A, Y,and W are as described herein. The present disclosure is also directed to pharmaceutical compositions comprising these compounds and methods of using these compounds as histone deacetylase inhibitors for the treatment of a disease or disorder, particularly for the treatment of cancer.

The application discloses an application of an indole dione piperazine compound in preparation of a drug for resisting prostate cancer. Experiments such as MTT, flow cytometry, protein chip, molecular docking, CETSA, transmission electron microscopy and zebra fish model prove that the compound significantly inhibits proliferation of prostate tumor cells such as PC-3, 22Rv1 and DU145, blocks division of PC-3 cells in the G1 phase, and induces apoptosis and necrotic apoptosis of PC-3 cells; the mechanism is that the compound directly combines NQO1 and NRF2, activates the HO-1 / NRF2 / NQO1 pathway, promotes excessive generation of ROS, and causes NQO1-dependent oxidative stress. The zebra fish model in vivo shows that the compound inhibits growth of prostate tumors. The application provides a lead compound with a new mechanism for preventing and treating prostate cancer and potential for overcoming drug resistance.

Provided is a conjugate of the formula (I) for treatment of tumors expressing PSMA, which comprises a PSMA-ligand with a linker and an antineoplastic agent monomethyl aluistatin E (MMAE). A composition for lyophilizate preparation based on the conjugate, a dosage form for therapy and obtained by the lyophilization of the composition, PSMA expressing a prostate tumor growth inhibition, a solution for infusions or injections containing the dosage form, reconstituted by a solvent, comprising 95% ethyl alcohol and polysorbate 80 at a mass ratio (30-60 wt %):(70-40 wt %), respectively, also provided. It is possible to obtain high affinity and selectivity of the action of the conjugates in relation to PSMA expressing cells using the conjugate of the formula (I).

To provide a process for preparing MDM2 inhibitors useful for treating solid tumors such as breast, colon, lung, and prostate tumors, as well as liquid tumors such as lymphomas and leukemias.SOLUTION: Provided are commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and intermediates thereof.SELECTED DRAWING: Figure 1

The invention discloses application of 19-hydroxybufalin in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of pharmaceutical preparations. The 19-hydroxybufalin is found to be targeted in vivo and in vitro for the first time, and the growth of prostate tumors is remarkably inhibited, so that the survival basis of tumor cells is fundamentally weakened, programmed death of the tumor cells is triggered, and tumor regression is effectively induced; a brand-new treatment approach is provided, namely, a non-classical drug target, namely HELLS, is degraded in a targeted manner, so that a new treatment choice is expected to be provided for a patient lacking existing target mutation; the provided 19-hydroxybufalin can be used for treating advanced prostate cancer, especially castration-resistant prostate cancer, and a new candidate treatment drug with great potential and a brand new treatment strategy are provided for effectively solving the problem that chemotherapy drug resistance and targeted therapy selection are limited in the castration-resistant prostate cancer at present.

The invention provides a machine learning analysis method and system based on prostate tumor multi-dimensional disease data and electronic equipment. The method comprises the following steps: S1, acquiring original image data, original clinical data and pathological results of prostate dominant focus tissues; s2, screening to obtain target radiomics characteristics, and establishing a radiomics model according to the target radiomics characteristics and in combination with the pathological result; establishing a deep learning model according to the original image data in combination with a pathological result; screening to obtain target clinical features, and establishing a clinical prediction model according to the target clinical features and in combination with the pathological result; s3, carrying out fusion analysis on the image omics model, the deep learning model and the clinical prediction model aiming at the prediction result of the prostate tumor multi-dimensional disease data, screening to obtain a target fusion feature, and establishing a multi-modal fusion model according to the target fusion feature in combination with a pathological result; and S4, establishing a two-dimensional column diagram based on the multi-modal fusion model.

The present application relates to a kind of compound with anti-androgen receptor activity and its use, the present application provides the compound shown in formula I, its racemate, stereoisomer, tautomer, solvate, polymorph or their pharmaceutically acceptable salt.The compound has good prostate tumor cell proliferation inhibitory activity and anti-AR activity.The compound has good in vivo metabolic properties, AUC and C max Both are higher, and the drug has good property, can be used for preventing and / or treating male hormone related disorder disease.The compound of the present application also has good hair production promoting effect, can effectively increase the number of hair follicle and the length of hair growth.

The invention provides an application of loranoside C in preparation of a medicine for treating prostatic cancer. Experiments prove that the erioside C can obviously inhibit the growth and survival of prostate cancer cells, has certain selectivity on the effects of the prostate cancer cells and normal prostate cells, can obviously inhibit the growth of prostate tumors, and shows a dose-effect relationship.

The application discloses RGD modified crocetin-paclitaxel co-loaded drug compound liposomes and a preparation method and application thereof, and belongs to the technical field of biological medicines. The RGD modified crocetin-paclitaxel co-loaded drug compound liposomes comprise RGD modified liposomes, paclitaxel and crocetin, wherein the RGD modified liposomes are used as a drug carrier to target and deliver the paclitaxel and the crocetin to prostate tumor cells, and the RGD modified liposomes are prepared by a film dispersion method or a reverse evaporation method. The prostate cancer targeted compound liposomes prepared by the application can increase the uptake of the prostate cancer cells, improve the in-vitro cytotoxicity of the prostate cancer cell line RM-1, and inhibit the growth of RM-1 ectopic solid tumors in mice, and does not cause obvious damage to other tissues.

The invention discloses a prostate tumor complete cycle intelligent management bed, and relates to the technical field of rehabilitation instruments.The prostate tumor complete cycle intelligent management bed comprises a supporting frame, a bed surface is fixedly installed on the upper surface of the supporting frame, a lifting assembly is arranged below the supporting frame, and an upper moving plate is arranged in the lifting assembly; two side plates are fixedly mounted on the upper surface of the upper moving plate, the two side plates are symmetrically distributed about the center line of the supporting frame, the two side plates are located on the front side and the rear side of the supporting frame correspondingly, the two side plates are rotationally connected with the supporting frame, and a mounting plate is arranged between the two side plates; two lower limb fixing devices are rotationally mounted on the right side of the mounting plate; a hip-knee linkage mechanism in natural gaits of lower limbs of a human body is simulated through inter-joint kinematics transmission so as to simulate motion functions of hip joints of the human body on different planes, and comprehensive and effective lower limb rehabilitation training is provided for a patient in combination with a unique force state coupling motion mode.

The invention relates to the technical field of tumor molecular diagnosis, and particularly discloses a primary prostate urothelium carcinoma (PUCP) typing method based on MTRNR2L12 expression characteristics and application of the primary prostate urothelium carcinoma (PUCP) typing method. The specific expression characteristics of the MTRNR2L12 gene in the primary prostatic urothelial carcinoma are systematically revealed from a plurality of links such as single cell separation and sequencing, data preprocessing and clustering, subtype division and CNV analysis, function enrichment analysis, public data integration and trajectory reconstruction, differential expression and clinical sample verification; therefore, the MTRNR2L12 can be used as a molecular marker for diagnosing the PUCP, and the accuracy of clinical early recognition is improved. The invention can be applied to molecular typing and auxiliary diagnosis of suspected prostate tumor samples, and has important clinical transformation potential.

The invention relates to the technical field of cell culture, and particularly discloses a culture device for prostate tumor cells and a using method thereof.The culture device comprises a hormone gradient generation assembly, and a dynamic control unit is installed at the top of the hormone gradient generation assembly; a plurality of groups of culture gradient diffusion assemblies are arranged between the dynamic control unit and the hormone gradient generation assembly; after the electrically-driven air supply unit is inflated and expanded, periodic pressure is applied to the cells when the silica gel pressure head passes through, mechanical stimulation is formed, the axial movement speed of the conical limiting support is set to push the culture medium to flow back and forth, and shear force is controlled; an electrically-driven air supply unit is used for controlling a compression expansion ball to inhale air so as to adjust interlayer staggered spaces on the inner sides of the interval containing grooves and controlling a culture solution injection pump set to inject hormone into diffusion gaps on the inner sides of the interval containing grooves, and then the culture solution injection pump set operates in a no-load mode to simulate air holes; and the mechanical stimulation culture of the tumor cells is completed after the circulating motion of the silica gel pressure head.

Provided in the present disclosure are a compound represented by formula I, and a racemate, stereoisomer, tautomer, solvate, polymorph, or pharmaceutically acceptable salts thereof. The compound has good prostate tumor cell proliferation inhibitory activity and anti-AR activity. The compound has good in-vivo metabolic properties, has high AUC and Cmax, is good in druggability, and can be used for preventing and / or treating androgen-related disorders. The compound provided by the invention also has a good hair growth promoting effect, and can effectively increase the number of hair follicles and the growth length of hair.

The present invention relates to an in vitro / ex vivo method for the evaluation of the aggressiveness and / or prognosis of a tumor in a subject, that comprises the evaluation of the expression of multiple genes identified in a molecular signature, whose high expression is associated with a worse prognosis for the patient, and therefore with greater tumor aggressiveness. The invention also relates to kits for determining the expression of genes belonging to the molecular signature, as well as their use for the evaluation of the aggressiveness and / or prognosis of a tumor in a subject, and to inhibitors of the expression or activity of the signature genes for use in the treatment of prostate cancer and male breast cancer.

The present invention relates to compounds of formula (I), processes for their preparation, and pharmaceutical compositions containing them as the active ingredient. Compounds of the present invention may be useful as mitochondrial KV1.3 inhibitors (mitoKV1.3) to treat cancer diseases and the like, including breast, colon, and prostate tumors, melanoma, smooth muscle, and skeletal muscle cancer, chronic lymphocytic leukemia, glioblastoma, and pancreatic ductal adenocarcinoma.

The application discloses a kind of prostate cancer lesion detection model construction method based on contrast image feature extraction, belong to image processing field, including the following steps: establishing training sample, establishing prostate cancer lesion detection model and training prostate cancer lesion detection model;Prostate tumor detection model contains space-time feature extraction network and target detection network.In the establishment training sample, based on time intensity curve correction algorithm can automatically extract arteriolar microbubble in ultrasonic contrast video from the time segment of appearance to peak value, and prostate tumor detection becomes more sensitive.The prostate cancer lesion detection model of the application can richly extract the space-time features and prostate cancer lesions in the training samples by virtue of the advantages of three-dimensional deep learning, can adapt to different sizes of prostate cancer lesions, and makes use of the dynamic characteristics of ultrasonic contrast, and thus can improve the prediction accuracy of the lesions.

The present invention discloses a PSMA-targeted PSMA-PARPi conjugate, as well as its preparation method and application. This conjugate uses PSMA-mediated active targeting to transport the compound to the tumor site, reducing its toxicity to healthy cells and normal tissues, improving prostate tumor selectivity, and enhancing anti-tumor effects. This invention addresses the occurrence of peripheral adverse reactions in the clinical use of PARP, increases the safety window, and provides a novel bifunctional molecular targeted drug for the clinical treatment of solid tumors such as prostate cancer. The general formula of the PSMA-PARPi conjugate is as follows: #imgabs0#

The invention relates to the field of auxiliary detection, in particular to a precise positioning method for prostate tumor cell therapy, and the method comprises the steps: obtaining an organ image collected by a collection terminal; dividing the organ image into a plurality of image areas, identifying nucleoplasm features of cell nucleuses in each image area, and analyzing feature obvious characterization values of each image area according to the nucleoplasm features so as to divide feature obvious degree categories of each image area; according to the method, the tumor cells in each image area are adaptively identified and positioned according to the feature obvious degree category, the prostate tumor cells can be accurately positioned, and the accuracy of tumor cell detection is improved.

The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

The present disclosure provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. In some embodiments, the antibodies of the disclosure bind human PSMA with high affinity and bind CD3 to induce proliferation of human T cells. The disclosure includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of tumor cells expressing PSMA. In some embodiments, the present disclosure provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD3 and a second antigen binding molecule that specifically binds human PSMA. In some embodiments, the bispecific antigen binding molecules of the present disclosure are capable of inhibiting the growth of prostate tumors expressing PSMA.The antibodies and bispecific antigen binding molecules of the disclosure are useful for the treatment of diseases and disorders where a targeted, upregulated or induced immune response is desirable and / or therapeutically advantageous. For example, the antibodies of the disclosure are useful for the treatment of various cancers.

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and / or therapeutically beneficial.